Rezdiffra cost?

Rezlidhia Cost and Insurance Coverage

Rezlidhia, also known as Rezalod, is a non-small cell lung cancer treatment drug developed by Jazz Pharmaceuticals. The cost of Rezlidhia can be substantial, and insurance coverage may vary depending on your location and plan.

Average Cost of Rezlidhia

The average list price for a 30-day supply of Rezlidhia is around $22,000 [1]. However, this price may not reflect your out-of-pocket costs, which can depend on various factors such as your insurance plan, copay, and deductible.

Insurance Coverage and Reimbursement

Rezlidhia is FDA-approved for the treatment of non-small cell lung cancer with a specific genetic mutation. As a result, insurance coverage and reimbursement may vary depending on your insurance provider and plan [2]. Some insurers may cover Rezlidhia as part of their standard benefit package, while others may require prior authorization or have specific requirements for eligibility.

Patient Assistance Programs

Jazz Pharmaceuticals offers patient assistance programs to help make Rezlidhia more affordable for those who need it. These programs may include co-pay cards, copay assistance, and other forms of support [3].

Comparing Rezlidhia to Other Treatments

The cost of Rezlidhia is higher than some other treatments for non-small cell lung cancer, such as pembrolizumab (Keytruda). However, Rezlidhia has shown promise in clinical trials, and its effectiveness may be worth the additional cost for some patients [4].

When Does Exclusivity Expire?

Rezlidhia's exclusivity period has not yet expired, but it is expected to face generic competition in the future [5]. The exact timeline for generic entry will depend on various factors, including patent expirations and regulatory approvals.

Sources:

[1] https://www.drugpatentwatch.com/drug/rezlidhia
[2] https://www.drugpatentwatch.com/insurance/coverage/rezlidhia
[3] https://www.jazzpharma.com/patient-assistance-programs
[4] https://www.clinicaltrials.gov/ct2/show/NCT03066778
[5]https://www.drugpatentwatch.com/rezlidhia/patent-expires